For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Nuvation Bio Inc’s stock clocked out at $8.01, up 1.65% from its previous closing price of $7.88. In other words, the price has increased by $1.65 from its previous closing price. On the day, 6.97 million shares were traded. NUVB stock price reached its highest trading level at $8.24 during the session, while it also had its lowest trading level at $7.82.
Ratios:
To gain a deeper understanding of NUVB’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.39 and its Current Ratio is at 8.48. In the meantime, Its Debt-to-Equity ratio is 0.64 whereas as Long-Term Debt/Eq ratio is at 0.60.
On November 19, 2025, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $12.
On September 30, 2025, Jefferies started tracking the stock assigning a Buy rating and target price of $10.Jefferies initiated its Buy rating on September 30, 2025, with a $10 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 26 ’25 when Liu Dongfang sold 10,000 shares for $8.00 per share. The transaction valued at 80,000 led to the insider holds 18,000 shares of the business.
Liu Dongfang sold 10,000 shares of NUVB for $75,000 on Nov 25 ’25. The CHIEF MEDICAL OFFICER now owns 18,000 shares after completing the transaction at $7.50 per share. On Nov 26 ’25, another insider, DONGFANG LIU, who serves as the Officer of the company, bought 10,000 shares for $8.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NUVB now has a Market Capitalization of 2746095872 and an Enterprise Value of 2254598912. For the stock, the TTM Price-to-Sale (P/S) ratio is 102.96 while its Price-to-Book (P/B) ratio in mrq is 8.42. Its current Enterprise Value per Revenue stands at 84.29 whereas that against EBITDA is -9.737.
Stock Price History:
The Beta on a monthly basis for NUVB is 1.53, which has changed by 1.762069 over the last 52 weeks, in comparison to a change of 0.12934029 over the same period for the S&P500. Over the past 52 weeks, NUVB has reached a high of $7.93, while it has fallen to a 52-week low of $1.54. The 50-Day Moving Average of the stock is 76.37%, while the 200-Day Moving Average is calculated to be 181.72%.
Shares Statistics:
It appears that NUVB traded 8.84M shares on average per day over the past three months and 14442570 shares per day over the past ten days. A total of 341.76M shares are outstanding, with a floating share count of 239.22M. Insiders hold about 30.42% of the company’s shares, while institutions hold 53.85% stake in the company. Shares short for NUVB as of 1763078400 were 66349138 with a Short Ratio of 7.50, compared to 1760486400 on 79205983. Therefore, it implies a Short% of Shares Outstanding of 66349138 and a Short% of Float of 31.540000000000003.
Earnings Estimates
The performance of Nuvation Bio Inc (NUVB) in the stock market is under the watchful eye of 1.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.2, with high estimates of -$0.12 and low estimates of -$0.47.
Analysts are recommending an EPS of between -$0.45 and -$0.45 for the fiscal current year, implying an average EPS of -$0.45. EPS for the following year is -$0.28, with 1.0 analysts recommending between -$0.28 and -$0.28.
Revenue Estimates
In. The current quarter, 8 analysts expect revenue to total $31.89M. It ranges from a high estimate of $49.8M to a low estimate of $14.37M. As of. The current estimate, Nuvation Bio Inc’s year-ago sales were $5.71MFor the next quarter, 8 analysts are estimating revenue of $29.37M. There is a high estimate of $36.7M for the next quarter, whereas the lowest estimate is $22.3M.
A total of 9 analysts have provided revenue estimates for NUVB’s current fiscal year. The highest revenue estimate was $70.8M, while the lowest revenue estimate was $35.41M, resulting in an average revenue estimate of $53.93M. In the same quarter a year ago, actual revenue was $7.87MBased on 9 analysts’ estimates, the company’s revenue will be $169.46M in the next fiscal year. The high estimate is $207.7M and the low estimate is $126.2M.
